期刊文献+

结直肠癌药物敏感基因检测与治疗的研究进展 被引量:4

Research Progress of Drug Sensitive Gene Test and Therapy for Colorectal Cancer
下载PDF
导出
摘要 个体化治疗是指通过患者体内的有关药物作用靶点、路径、代谢等评估药物对患者可能的作用,提高治疗的针对性、避免反复尝试与不良反应,提高用药的安全性和有效性。通过药物敏感性基因检测,实现对结直肠癌化疗药物敏感性和疗效预测,进而优化治疗方案,提高疗效、减少无效治疗。结直肠癌患者选择化疗方案或靶向治疗之前进行药敏基因检测是实现个体化治疗的必经之路。 Individualized treatment to improve the pertinence, avoid repeated trial and adverse reactions, and increase the safety and efficacy through assessment of the possible action on patients through targets, paths, and metabolics of the medication. Drug sensitivity genetic testing can realize colorectal cancer chemo- therapy drug sensitivity and efficacy prediction, so as to optimize the treatment plan,improve the efficacy and reduce the ineffective treatment. Patients with colorectal cancer's drug-sensitive gene detection prior to chem- otherapy or targeted therapy is the only way to achieve individualized treatment.
出处 《医学综述》 2014年第5期810-813,共4页 Medical Recapitulate
关键词 基因检测 结直肠癌 治疗 Gene test Colorectal cancer Therapy
  • 相关文献

参考文献35

  • 1Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.International Multicentre Pooled Analysis of Colon Cancer Trials(IMPACT) investigators[J] .Lancet,1995,345(8955):939-944.
  • 2Twelves C,Wong A,Nowacki MP,et al.Capecitabine as adjuvant treatment for stage Ⅲcolon cancer[J] .N Engl J Med,2005,352(26):2696-2704.
  • 3Ichikawa W,Takahashi T,Suto K,et al.Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen[J] .Clin Cancer Res,2006,12(13):3928-3934.
  • 4Marsh S,Mckay JA,Cassidy J,et al.Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer[J] .Int J Oncol,2001,19(2):383-386.
  • 5Villafranca E,Okruzhnov Y,Dominguez MA,et al.Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer[J] .J Clin Oncol,2001,19(6):1779-1786.
  • 6Tan BR,Thomas F,Myerson RJ,et al.Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma[J] .J Clin Oncol,2011,29(7):875-883.
  • 7Koopman M,Venderbosch S,van Tinteren H,et al.Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer,a retrospective analysis of the phase Ⅲ randomized CAIRO study[J] .Eur J Cancer,2009,45(11):1999-2006.
  • 8Milano G,Etienne MC.Potential importance of dihydropyrimidine dehydrogenase(DPD) in cancer chemotherapy[J] .Pharmacogenetics,1994,4(6):301-306.
  • 9Salonga D,Danenberg KD,Johnson M,et al.Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase,thymidylate synthase and thymidine phosphorylase[J] .Clin Cancer Res,2000,6(4):1322-1327.
  • 10Ciccolini J,Gross E,Dahan L,et al.Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities:hype or hope?[J] .Clin Colorectal Cancer,2010,9(4):224-228.

同被引文献36

  • 1张华杰.应用中西医结合的方法治疗老年结直肠癌的临床疗效观察[J].求医问药(下半月),2013(3):312-313. 被引量:4
  • 2Shii K, Kanou S, Takei R, et al. Our experience with panitumumab used for patients with metastatic colorectal cancer [ J ]. Gan To Ka- gaku Ryoho ,2013,40( 1 ) :67 - 69.
  • 3Ku GY,Haaland BA,De Lima Lopes G Jr. Cetuximab in the first - line treatment of K - ras wild - type metastatic colorectal cancer: The choice and schedule of fluoropyrimidine matters [ J ]. CancerChemother Pharmaeo1,2012,70 (2) :231 - 238.
  • 4Koopman M, Yenderbosch S, Van Tinteren H, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced eoloreetal cancer, a retrospective analysis of the phase 1~ random- ized CAIRO study [ J]. Eur J Cancer,2009,45 ( 11 ) : 1999 - 2006.
  • 5Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase(DPD) in cancer chemotherapy [ J ]. Pharmacoge- netics,1994,4(6) :301 -306.
  • 6Salonga D, Danerlberg KD, Johnson M, et al. Colorectal tumors re- sponding to 5 - fluornuracil have low gene expression levels of di- hydropyrimidine dehydrogenase, thymidylate synthase and thymi- dine phosphorylase [ J ]. Clin Cancer Res, 2000,6 (4) : 1322 - 1327.
  • 7Iehikawa W, Uetake H, Shirota Y, et al. Combination of dihydropy- rimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoro- pyrimidine- based chemotherapy for metastatic colorectal cancer [ J]. Clin Cancer IRes ,2003,9:786 - 791.
  • 8Sugihara K, Hirayama R. Prognostic significance of thymidylate syn- thase, dihydropyrimidine dehydrogenase and thymidine phosphoryl- ase protein expression in colorectal cancer patients treated with or without 5 - fluorouracil - based chemotherapy [ J ]. Ann Oncol, 2008,19:915 - 919.
  • 9Castillo - Fernandez O, Santibaez M, Bauza A, et al. Methylenetet- rahyd - Rofolate reductase polymorphism( 677C > T)predicts long time to pro - gression in metastic colon cancer treated with 5 - flu- orouracil and folinic acid [ J]. Arch Med Res,2010,41 (6) :430 - 435.
  • 10Sharp L,Little J. Polymorphisms in genes involved in folate metab- olism and colorectal neoplasia:A HuGE review [J]. Am J Epide- miol,2004,159:423 - 443.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部